AmoyDx's KRAS Kit Approved by Chinese SFDA

According to the company, the kit is the first molecular diagnostic assay to receive approval in China for use in personalized clinical testing in oncology.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories